Medicinal Chemistry of Inhibitors of 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD1)

11β-Hydroxysteroid dehydrogenase type 1 (11β-HSD1) is the enzyme primarily responsible for the regulation of intracellular cortisol levels. Inhibition of 11β-HSD1 is an attractive mechanism for the treatment of obesity and other elements of the metabolic syndrome. Emerging literature also supports a...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of medicinal chemistry 2014-06, Vol.57 (11), p.4466-4486
Hauptverfasser: Scott, James S, Goldberg, Frederick W, Turnbull, Andrew V
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 4486
container_issue 11
container_start_page 4466
container_title Journal of medicinal chemistry
container_volume 57
creator Scott, James S
Goldberg, Frederick W
Turnbull, Andrew V
description 11β-Hydroxysteroid dehydrogenase type 1 (11β-HSD1) is the enzyme primarily responsible for the regulation of intracellular cortisol levels. Inhibition of 11β-HSD1 is an attractive mechanism for the treatment of obesity and other elements of the metabolic syndrome. Emerging literature also supports a potential role in the treatment of other unmet medical needs including Alzheimer’s disease, vascular inflammation, cardiovascular disease, and glaucoma. The aim of this article is to review the medicinal chemistry literature around small molecule approaches to developing synthetic inhibitors of 11β-HSD1 and to highlight key compounds that have resulted from the efforts of both industrial and academic groups. The reported data from 11β-HSD1 inhibitors that have progressed into the clinic are summarized followed by a perspective from the authors.
doi_str_mv 10.1021/jm4014746
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1535626580</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1535626580</sourcerecordid><originalsourceid>FETCH-LOGICAL-a315t-94a7769f9ec91530cda670331d160a0f52b09c478a8efe262f6895a7bf2a60153</originalsourceid><addsrcrecordid>eNptkLFOwzAQhi0EoqUw8AIoC1I7BM6O7cQjaoFWAjFQBqbISWyaKqmLnUjktXgQnglXKZ2YTnf67pf-D6FLDDcYCL5d1xQwjSk_QkPMCIQ0AXqMhgCEhISTaIDOnFsDQIRJdIoGhBJBRcKG6P1ZFWVebmQVTFeqLl1ju8DoYLFZlVnZGOt2G8Y_3-G8K6z56lyjrCmLYKZWu8OH2kingmW3VQEOxj35OsOTc3SiZeXUxX6O0NvD_XI6D59eHhfTu6dQRpg1oaAyjrnQQuUCswjyQvIYoggXmIMEzUgGIqdxIhOllS-jeSKYjDNNJAf_MULjPndrzWerXJP6FrmqKrlRpnWpRxgnnCXg0UmP5tY4Z5VOt7aspe1SDOnOZHow6dmrfWyb1ao4kH_qPHDdAzJ36dq01jt0_wT9AkNoeHc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1535626580</pqid></control><display><type>article</type><title>Medicinal Chemistry of Inhibitors of 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD1)</title><source>MEDLINE</source><source>American Chemical Society (ACS) Journals</source><creator>Scott, James S ; Goldberg, Frederick W ; Turnbull, Andrew V</creator><creatorcontrib>Scott, James S ; Goldberg, Frederick W ; Turnbull, Andrew V</creatorcontrib><description>11β-Hydroxysteroid dehydrogenase type 1 (11β-HSD1) is the enzyme primarily responsible for the regulation of intracellular cortisol levels. Inhibition of 11β-HSD1 is an attractive mechanism for the treatment of obesity and other elements of the metabolic syndrome. Emerging literature also supports a potential role in the treatment of other unmet medical needs including Alzheimer’s disease, vascular inflammation, cardiovascular disease, and glaucoma. The aim of this article is to review the medicinal chemistry literature around small molecule approaches to developing synthetic inhibitors of 11β-HSD1 and to highlight key compounds that have resulted from the efforts of both industrial and academic groups. The reported data from 11β-HSD1 inhibitors that have progressed into the clinic are summarized followed by a perspective from the authors.</description><identifier>ISSN: 0022-2623</identifier><identifier>EISSN: 1520-4804</identifier><identifier>DOI: 10.1021/jm4014746</identifier><identifier>PMID: 24294985</identifier><language>eng</language><publisher>United States: American Chemical Society</publisher><subject>11-beta-Hydroxysteroid Dehydrogenase Type 1 - antagonists &amp; inhibitors ; Alzheimer Disease - drug therapy ; Alzheimer Disease - enzymology ; Animals ; Cardiovascular Diseases - drug therapy ; Cardiovascular Diseases - enzymology ; Clinical Trials as Topic ; Glaucoma - drug therapy ; Glaucoma - enzymology ; Glucocorticoids - metabolism ; Humans ; Metabolic Syndrome - drug therapy ; Metabolic Syndrome - enzymology</subject><ispartof>Journal of medicinal chemistry, 2014-06, Vol.57 (11), p.4466-4486</ispartof><rights>Copyright © 2013 American Chemical Society</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a315t-94a7769f9ec91530cda670331d160a0f52b09c478a8efe262f6895a7bf2a60153</citedby><cites>FETCH-LOGICAL-a315t-94a7769f9ec91530cda670331d160a0f52b09c478a8efe262f6895a7bf2a60153</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://pubs.acs.org/doi/pdf/10.1021/jm4014746$$EPDF$$P50$$Gacs$$H</linktopdf><linktohtml>$$Uhttps://pubs.acs.org/doi/10.1021/jm4014746$$EHTML$$P50$$Gacs$$H</linktohtml><link.rule.ids>314,776,780,2752,27053,27901,27902,56713,56763</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24294985$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Scott, James S</creatorcontrib><creatorcontrib>Goldberg, Frederick W</creatorcontrib><creatorcontrib>Turnbull, Andrew V</creatorcontrib><title>Medicinal Chemistry of Inhibitors of 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD1)</title><title>Journal of medicinal chemistry</title><addtitle>J. Med. Chem</addtitle><description>11β-Hydroxysteroid dehydrogenase type 1 (11β-HSD1) is the enzyme primarily responsible for the regulation of intracellular cortisol levels. Inhibition of 11β-HSD1 is an attractive mechanism for the treatment of obesity and other elements of the metabolic syndrome. Emerging literature also supports a potential role in the treatment of other unmet medical needs including Alzheimer’s disease, vascular inflammation, cardiovascular disease, and glaucoma. The aim of this article is to review the medicinal chemistry literature around small molecule approaches to developing synthetic inhibitors of 11β-HSD1 and to highlight key compounds that have resulted from the efforts of both industrial and academic groups. The reported data from 11β-HSD1 inhibitors that have progressed into the clinic are summarized followed by a perspective from the authors.</description><subject>11-beta-Hydroxysteroid Dehydrogenase Type 1 - antagonists &amp; inhibitors</subject><subject>Alzheimer Disease - drug therapy</subject><subject>Alzheimer Disease - enzymology</subject><subject>Animals</subject><subject>Cardiovascular Diseases - drug therapy</subject><subject>Cardiovascular Diseases - enzymology</subject><subject>Clinical Trials as Topic</subject><subject>Glaucoma - drug therapy</subject><subject>Glaucoma - enzymology</subject><subject>Glucocorticoids - metabolism</subject><subject>Humans</subject><subject>Metabolic Syndrome - drug therapy</subject><subject>Metabolic Syndrome - enzymology</subject><issn>0022-2623</issn><issn>1520-4804</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNptkLFOwzAQhi0EoqUw8AIoC1I7BM6O7cQjaoFWAjFQBqbISWyaKqmLnUjktXgQnglXKZ2YTnf67pf-D6FLDDcYCL5d1xQwjSk_QkPMCIQ0AXqMhgCEhISTaIDOnFsDQIRJdIoGhBJBRcKG6P1ZFWVebmQVTFeqLl1ju8DoYLFZlVnZGOt2G8Y_3-G8K6z56lyjrCmLYKZWu8OH2kingmW3VQEOxj35OsOTc3SiZeXUxX6O0NvD_XI6D59eHhfTu6dQRpg1oaAyjrnQQuUCswjyQvIYoggXmIMEzUgGIqdxIhOllS-jeSKYjDNNJAf_MULjPndrzWerXJP6FrmqKrlRpnWpRxgnnCXg0UmP5tY4Z5VOt7aspe1SDOnOZHow6dmrfWyb1ao4kH_qPHDdAzJ36dq01jt0_wT9AkNoeHc</recordid><startdate>20140612</startdate><enddate>20140612</enddate><creator>Scott, James S</creator><creator>Goldberg, Frederick W</creator><creator>Turnbull, Andrew V</creator><general>American Chemical Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20140612</creationdate><title>Medicinal Chemistry of Inhibitors of 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD1)</title><author>Scott, James S ; Goldberg, Frederick W ; Turnbull, Andrew V</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a315t-94a7769f9ec91530cda670331d160a0f52b09c478a8efe262f6895a7bf2a60153</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>11-beta-Hydroxysteroid Dehydrogenase Type 1 - antagonists &amp; inhibitors</topic><topic>Alzheimer Disease - drug therapy</topic><topic>Alzheimer Disease - enzymology</topic><topic>Animals</topic><topic>Cardiovascular Diseases - drug therapy</topic><topic>Cardiovascular Diseases - enzymology</topic><topic>Clinical Trials as Topic</topic><topic>Glaucoma - drug therapy</topic><topic>Glaucoma - enzymology</topic><topic>Glucocorticoids - metabolism</topic><topic>Humans</topic><topic>Metabolic Syndrome - drug therapy</topic><topic>Metabolic Syndrome - enzymology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Scott, James S</creatorcontrib><creatorcontrib>Goldberg, Frederick W</creatorcontrib><creatorcontrib>Turnbull, Andrew V</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of medicinal chemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Scott, James S</au><au>Goldberg, Frederick W</au><au>Turnbull, Andrew V</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Medicinal Chemistry of Inhibitors of 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD1)</atitle><jtitle>Journal of medicinal chemistry</jtitle><addtitle>J. Med. Chem</addtitle><date>2014-06-12</date><risdate>2014</risdate><volume>57</volume><issue>11</issue><spage>4466</spage><epage>4486</epage><pages>4466-4486</pages><issn>0022-2623</issn><eissn>1520-4804</eissn><abstract>11β-Hydroxysteroid dehydrogenase type 1 (11β-HSD1) is the enzyme primarily responsible for the regulation of intracellular cortisol levels. Inhibition of 11β-HSD1 is an attractive mechanism for the treatment of obesity and other elements of the metabolic syndrome. Emerging literature also supports a potential role in the treatment of other unmet medical needs including Alzheimer’s disease, vascular inflammation, cardiovascular disease, and glaucoma. The aim of this article is to review the medicinal chemistry literature around small molecule approaches to developing synthetic inhibitors of 11β-HSD1 and to highlight key compounds that have resulted from the efforts of both industrial and academic groups. The reported data from 11β-HSD1 inhibitors that have progressed into the clinic are summarized followed by a perspective from the authors.</abstract><cop>United States</cop><pub>American Chemical Society</pub><pmid>24294985</pmid><doi>10.1021/jm4014746</doi><tpages>21</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0022-2623
ispartof Journal of medicinal chemistry, 2014-06, Vol.57 (11), p.4466-4486
issn 0022-2623
1520-4804
language eng
recordid cdi_proquest_miscellaneous_1535626580
source MEDLINE; American Chemical Society (ACS) Journals
subjects 11-beta-Hydroxysteroid Dehydrogenase Type 1 - antagonists & inhibitors
Alzheimer Disease - drug therapy
Alzheimer Disease - enzymology
Animals
Cardiovascular Diseases - drug therapy
Cardiovascular Diseases - enzymology
Clinical Trials as Topic
Glaucoma - drug therapy
Glaucoma - enzymology
Glucocorticoids - metabolism
Humans
Metabolic Syndrome - drug therapy
Metabolic Syndrome - enzymology
title Medicinal Chemistry of Inhibitors of 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD1)
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T09%3A41%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Medicinal%20Chemistry%20of%20Inhibitors%20of%2011%CE%B2-Hydroxysteroid%20Dehydrogenase%20Type%201%20(11%CE%B2-HSD1)&rft.jtitle=Journal%20of%20medicinal%20chemistry&rft.au=Scott,%20James%20S&rft.date=2014-06-12&rft.volume=57&rft.issue=11&rft.spage=4466&rft.epage=4486&rft.pages=4466-4486&rft.issn=0022-2623&rft.eissn=1520-4804&rft_id=info:doi/10.1021/jm4014746&rft_dat=%3Cproquest_cross%3E1535626580%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1535626580&rft_id=info:pmid/24294985&rfr_iscdi=true